ATZUMI - (EQ 5.2MG BASE ; Powder)

Generic Name	DIHYDROERGOTAMINE MESYLATE	**Innovator**	SATSUMA PHARMS
Dosage	EQ 5.2MG BASE ; Powder	**Branded US Sales**	Less Than $1000 mn
Probable FTF	None	**Known Para IV Filers**	None
Other ANDA developers	None	**Tentative Approvals**	None
Final Approvals	None	**Generic Launches**	None
Indication	ATZUMI is an ergotamine derivative indicated for the acute treatment of migraine with or without aura in adults.		
Complexities	Yes		

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.

Executive Summary

Please Contact contact@researchdelta.com to get Detailed Information.

Patent Status

Please Contact contact@researchdelta.com to get Detailed Information.

Launch Timelines and Competition

Please Contact contact@researchdelta.com to get Detailed Information.

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.